



Abomics Ltd - Genomic Medicine Expertise

Abomics is a health technology firm that provides healthcare professionals with new approaches to personalized medicine. The company was founded in 2013 in Finland and comprises of admitted specialists in several fields of science. Abomics designs cutting-edge integrated decision support tools in collaboration with providers of EHR systems and laboratory IT systems. All Abomics' products have been designed to meet the extensive requirements of healthcare professionals.



Jari Forsström
CEO, MD
jari.forsstrom@abomics.fi
+358 40 544 1809



abomics.fi



info@abomics.fi



Abomics



@Abomics_fi



Abomics Oy

Tykistökatu 4 B, FI-20520 Turku, Finland



GeneCa

Decision support tool for targeted cancer medicine

GeneCa is a search engine for oncologists that makes information search on targeted cancer drugs quick and easy. This tool aids the physician in making well-informed decisions when prescribing cancer medications. GeneCa is constantly updated with information such as adverse effects, target molecules and clinical trials. GeneCa gathers necessary information from many different sources in one place and creates significant time savings for the oncologist.



GeneCa – Decision support tool for targeted cancer medicine

New targeted drugs enter the market at an ever-increasing pace and key information is updated frequently. This creates new challenges for oncologists, as new information must be searched from many different sources. Keeping up to date with all the changes becomes difficult and time-consuming. The solution is a comprehensive tool that gathers essential information from different official sources and processes it into clear instructions for the treating physician. GeneCa is a first-of-a-kind decision support tool that delivers relevant data straight to the oncologist's dashboard.

Choosing the right cancer drug becomes easier

In the expanding world of targeted cancer medication the oncologist needs a proper decision support tool to pick the right drug for the right type of cancer.

Significant time savings

Comprehensive data in one place reduces the workload of the oncologist, saving minutes of precious working time each day.

Patient safety increases

The oncologist is able to make well-informed decisions based on up-to-date research. Adverse effects can be managed pre-emptively and risks to the patient are identified beforehand.

Keeps you updated

Automatically updates with the newest drugs, clinical trials, research data and official recommendations.


GeneCa contains:

- Summary of product characteristics (SPC) of all locally available targeted cancer drugs
- Drug target molecules listed by the local healthcare authority
- Mutations of drug target molecules in different cancer types
- Registration trials
- Phase III and IV clinical trials
- Tables of adverse effects
- Treatment recommendations for adverse effects

The data presented in GeneCa is gathered and maintained by Abomics Ltd. GeneCa has been developed in collaboration with healthcare authorities and leading oncologists in order to meet the rigorous standards of the modern healthcare system.


Continually growing database for continually growing industry

Target drugs in late-stage development (2014)




Source: Milne 2014, Nat Rev Drug Discov. 13:324-5

Global Oncology Market Forecast



Source: IMS Health MIDAS, Dec 2014; IMS Health Market Prognosis, March 2015



The screenshot shows the GeneCa web application interface. At the top, there is a search bar with the word 'lung' entered. Below the search bar, there is a table of search results. The table has columns for Trade name, Active Ingredient, Indications, Target molecule, Vendor, and More Information. The results are sorted by relevance, with 'Avastin' (bevacizumab) at the top. The table also includes links for Reimbursement, Adv. reactions, and Trials for each drug.

Trade name	Active Ingredient	Indications	Target molecule	Vendor	More Information
Avastin	bevacizumab	colorectal cancer, breast cancer, lung cancer, kidney cancer, ovarian cancer	VEGFA	Orifarm	Reimbursement, Adv. reactions, Trials
Avastin	bevacizumab	colorectal cancer, breast cancer, lung cancer, kidney cancer, ovarian cancer	VEGFA	Roche	Reimbursement, Adv. reactions, Trials
Giotrif	afatinib	lung cancer	EGFR (HER1), ERBB2 (HER2), ERBB4 (HER4)	Boehringer Ingelheim	Reimbursement, Adv. reactions, Trials
Iressa	gefitinib	lung cancer	EGFR (HER1)	Astrazeneca	Reimbursement, Adv. reactions, Trials
Tarceva	erlotinib	lung cancer, pancreatic cancer	EGFR (HER1)	Roche	Reimbursement, Adv. reactions, Trials
Xalkori	crizotinib	lung cancer	ALK, MET (HGFR), MST1R (RON)	Pfizer	Reimbursement, Adv. reactions, Trials

- Search option is able to search even from unfinished words
- Advanced search allows user to search medicine with specific criteria
- Search results can be sorted based on any search criteria
- Search results display extensive information on local reimbursements, adverse reactions and trials